Compare FIVE & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVE | MDGL |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 12.1B |
| IPO Year | 2012 | 2005 |
| Metric | FIVE | MDGL |
|---|---|---|
| Price | $232.58 | $521.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 12 |
| Target Price | $236.00 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 1.1M | 277.0K |
| Earning Date | 06-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 40.65 | ★ 41.32 |
| EPS | ★ 6.47 | N/A |
| Revenue | ★ $4,764,147,000.00 | $180,133,000.00 |
| Revenue This Year | $14.44 | $58.39 |
| Revenue Next Year | $9.37 | $48.55 |
| P/E Ratio | $36.04 | ★ N/A |
| Revenue Growth | ★ 22.90 | N/A |
| 52 Week Low | $73.92 | $265.00 |
| 52 Week High | $251.63 | $615.00 |
| Indicator | FIVE | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 54.17 |
| Support Level | $213.25 | $503.93 |
| Resistance Level | $235.08 | $539.17 |
| Average True Range (ATR) | 8.64 | 16.01 |
| MACD | 0.01 | -3.37 |
| Stochastic Oscillator | 52.07 | 42.85 |
Five Below Inc is a specialty value retailer offering a broad range of trend-right, high-quality products loved by the kid and the kid in all of customers. The Company's edited assortment of products includes select brands and licensed merchandise. The Company also sells its merchandise on the internet, through the Company's e-commerce website and mobile app, offering home delivery and the option to buy online and pick up in store. Additionally, the Company sells merchandise through on-demand third-party delivery services to enable its customers to shop online and receive convenient delivery. It derives revenue from sales of the Company's merchandise to customers.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.